



3rd Edition

MM03

Molecular Diagnostic Methods for Infectious Diseases

This report addresses topics relating to clinical applications, amplified and nonamplified nucleic acid methods, selection and qualification of nucleic acid sequences, establishment and evaluation of test performance characteristics, inhibitors, and interfering substances, controlling false-positive reactions, reporting and interpretation of results, quality assurance, regulatory issues, and recommendations for manufacturers and clinical laboratories.

A CLSI report for global application.

Clinical and Laboratory Standards Institute

Setting the standard for quality in clinical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing clinical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are addressed according to the consensus process by a committee of experts.

Appeals Process

If it is believed that an objection has not been adequately addressed, the process for appeals is documented in the CLSI Standards Development Policies and Process document.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For further information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
950 West Valley Road, Suite 2500
Wayne, PA 19087 USA
P: 610.688.0100
F: 610.688.0700
www.clsi.org
standard@clsi.org

MM03, 3rd ed.
February 2015
Replaces MM03-A2

Molecular Diagnostic Methods for Infectious Diseases

Stephen P. Day, PhD
Cynthia L. Jackson, PhD
Frederick S. Nolte, PhD, D(ABBM), F(AAM)
Zivana Tezak-Fragale, PhD

Abstract

Nucleic acid methods for the detection and characterization of microorganisms in clinical specimens are now firmly established in laboratory medicine. These methods offer opportunities for clinical laboratories to provide more rapid and accurate results, and have changed the practice of clinical microbiology and infectious diseases. Clinical and Laboratory Standards Institute document MM03—*Molecular Diagnostic Methods for Infectious Diseases* addresses topics relating to clinical applications, amplified and nonamplified nucleic acid methods, selection and qualification of nucleic acid sequences, establishment and evaluation of test performance characteristics, inhibitors, and interfering substances, controlling false-positive reactions, reporting and interpretation of results, QA, regulatory issues, and recommendations for manufacturers and clinical laboratories.

Clinical and Laboratory Standards Institute (CLSI). *Molecular Diagnostic Methods for Infectious Diseases*. 3rd ed. CLSI report MM03 (ISBN 1-56238-997-1 [Print]; ISBN 1-56238-998-X [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2015.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If you or your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org.



CLINICAL AND
LABORATORY
STANDARDS
INSTITUTE®

MM03, 3rd ed.

Copyright ©2015 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

Suggested Citation

CLSI. *Molecular Diagnostic Methods for Infectious Diseases*. 3rd ed. CLSI report MM03. Wayne, PA: Clinical and Laboratory Standards Institute; 2015.

Previous Editions:

March 1994, December 1995, April 2005, February 2006

ISBN 1-56238-997-1 (Print)
ISBN 1-56238-998-X (Electronic)
ISSN 1558-6502 (Print)
ISSN 2162-2914 (Electronic)

Volume 35, Number 5

Committee Membership

Consensus Committee on Molecular Methods

Frederick S. Nolte, PhD,
D(ABMM), F(AAM)
Chairholder
Medical University Hospital
Authority
USA

Barbara Zehnbaauer, PhD,
FACMG, FACB
Vice-Chairholder
Centers for Disease Control and
Prevention
USA

Sherry A. Dunbar, PhD
Luminex Corporation
USA

Helen Fernandes, PhD
Weill Cornell Medical College
USA

Tina M. Hambuch, PhD
Illumina, Inc.
USA

Charles E. Hill, MD, PhD
Emory University Hospital
USA

Penny Keller, BS, MB(ASCP)
Centers for Medicare & Medicaid
Services
USA

Thomas J. Lenk, PhD
Celera Diagnostics
USA

Yi-Wei Tang, MD, PhD,
D(ABMM)
Memorial Sloan Kettering Cancer
Center
USA

Zivana Tezak-Fragale, PhD
FDA Center for Devices and
Radiological Health
USA

Working Group on Molecular Diagnostic Methods for Infectious Diseases

Stephen P. Day, PhD
USA

Cynthia L. Jackson, PhD
Rhode Island Hospital
USA

Frederick S. Nolte, PhD,
D(ABMM), F(AAM)
Medical University Hospital
Authority
USA

Zivana Tezak-Fragale, PhD
FDA Center for Devices and
Radiological Health
USA

Staff

Clinical and Laboratory Standards
Institute
USA

Luann Ochs, MS
Senior Vice President – Operations

Marcy Hackenbrack, MCM,
M(ASCP)
Project Manager

Megan L. Tertel, MA
Editorial Manager

Joanne P. Christopher, MA
Editor

Patrice E. Polgar
Editor

Acknowledgment

CLSI, the Consensus Committee on Molecular Methods, and the Working Group on Molecular Diagnostic Methods for Infectious Diseases gratefully acknowledge the authors of the previous edition of MM03 (*Molecular Diagnostic Methods for Infectious Diseases; Approved Guideline—Second Edition*), which has been minimally revised by the working group to develop this report:

Judy C. Arbique, ART(CSMLS), CLS(NCA)
Franklin R. Cockerill, III, MD
Peter J. Dailey, PhD, MPH
David Hillyard, MD
Sherrol McDonough, PhD
Richard F. Meyer, PhD
Frederick S. Nolte, PhD, D(ABMM), F(AAM)
Roxanne G. Shively, MS

This is a preview of "CLSI MM03-Ed3". [Click here to purchase the full version from the ANSI store.](#)

MM03, 3rd ed.

Contents

Abstract.....	i
Committee Membership.....	iii
Foreword.....	vii
Chapter 1: Introduction.....	1
1.1 Scope.....	1
1.2 Background.....	2
1.3 Standard Precautions.....	2
1.4 Terminology.....	2
Chapter 2: Applications.....	9
2.1 Utility of Molecular Diagnostic Tests for Infectious Diseases.....	9
2.2 Screening or Initial Testing.....	10
2.3 Confirmatory and Supplemental Testing.....	11
Chapter 3: Specimen Collection, Transport, and Processing.....	13
Chapter 4: Contributors to False-Negative Results and Controls.....	15
4.1 Detection of Inhibitors and Interfering Substances.....	16
4.2 Inhibitory Samples.....	17
Chapter 5: Methods.....	19
5.1 Physical and Chemical Methods for Nucleic Acid Detection.....	19
5.2 Detection Formats.....	20
5.3 Nucleic Acid Amplification Technologies.....	23
5.4 Real-Time Polymerase Chain Reaction Instruments.....	26
Chapter 6: Selection and Qualification of Nucleic Acid Sequences.....	29
6.1 Target Region.....	29
6.2 Polymerase Chain Reaction Primer Sequence Selection.....	29
6.3 Hybridization Probe Sequence Selection.....	30
6.4 Fluorescence Resonance Energy Transfer Probes.....	31
6.5 Probe and Primer Forms and Purity.....	33
Chapter 7: Establishment and Evaluation of Performance Characteristics of Molecular Diagnostic Tests.....	35
7.1 Limit of Detection (Analytical Sensitivity).....	35
7.2 Analytical Specificity.....	36
7.3 Precision.....	36
7.4 Cutoff Values.....	36
7.5 Diagnostic Sensitivity.....	37
7.6 Diagnostic Specificity.....	37
7.7 Predictive Values.....	38
7.8 Diagnostic Accuracy.....	38
7.9 Diagnostic Value.....	38
7.10 Test Limitations.....	39
7.11 Implementation of US Food and Drug Administration–Cleared Tests.....	39
Chapter 8: Quality Assurance.....	41

MM03, 3rd ed.

Contents (Continued)

8.1	Laboratory Design and Practices	41
8.2	Instruments.....	43
8.3	Quality Assurance During Development of Molecular Diagnostic Tests.....	43
8.4	Control Materials	44
8.5	Selecting Organism Strains for Analytical Studies.....	46
8.6	Preparing Nucleic Acid Controls	46
8.7	Types of Testing During Assay Development.....	47
8.8	Quality Assurance for Implementation of Molecular Diagnostic Tests.....	54
8.9	Trend Analysis.....	55
8.10	Proficiency Testing.....	55
8.11	Controlling False-Positive Nucleic Acid Target Amplification Reactions.....	55
Chapter 9: Reporting of Results.....		61
9.1	Organism and Nucleic Acid Target	61
9.2	Equivocal Results	61
9.3	Reference Range	61
9.4	Critical Results.....	61
9.5	Test Limitations	61
9.6	Interpretation.....	62
9.7	Clarifying Statements	62
Chapter 10: Recommendations for Manufacturers and Clinical Laboratories.....		63
10.1	Regulatory Requirements	63
10.2	Recommendations to Assay Developers.....	63
10.3	Recommendations for Clinical Laboratories	64
10.4	Selection of Referral Laboratories	64
Chapter 11: Conclusion.....		66
Chapter 12: Supplemental Information.....		66
References.....		67
Additional References.....		73
Appendix. Nucleic Acid Amplification Technologies.....		74
The Quality Management System Approach.....		90
Related CLSI Reference Materials		92

Foreword

MM03 was originally published as an approved guideline in 1995. It was the first of what was to become many CLSI molecular diagnostics guidelines, and the first molecular microbiology consensus guideline published. Molecular microbiology is the application of nucleic acid methods to the diagnosis and management of patients with infectious diseases. The field has advanced enormously since the publication of the first approved edition of MM03 and is now an integral part of laboratory medicine.

Overview of Changes

With the change in format and category definitions for all CLSI documents, MM03 has been recategorized as a report and replaces MM03-A2. Although MM03 has been revised for the purpose of keeping information current, the revisions do not significantly affect the scope or purpose of the document, nor do they change the methodology used. Revisions to the document include:

- Formatting and template design have been updated to reflect current CLSI style.
- References to most trademarked products have been deleted.
- CLSI references have been updated to reflect current document numbers and editions.
- International Organization for Standardization definitions and references have been updated to reflect current editions.
- New test descriptions and figures have been added to the text and the appendix in order to reflect current technology.

Note that the trade name TaqMan[®] is included as a reference to Figure 1 of this document. It is Clinical and Laboratory Standards Institute's policy to avoid using a trade name unless the product identified is the only one available, or it serves solely as an illustrative example of the procedure, practice, or material described. In this case, the working group and consensus committee believe the illustration derived from the published reference is an important descriptive adjunct to the document. In such cases, it is acceptable to use the product's trade name when the illustration is being reprinted from a referenced publication. It should be understood that information on this product in this document also applies to any equivalent products.

Key Words

Development, implementation, infectious disease, molecular methods, molecular microbiology, nucleic acid amplification, quality assurance, reporting, validation, verification

This is a preview of "CLSI MM03-Ed3". [Click here to purchase the full version from the ANSI store.](#)

MM03, 3rd ed.

Molecular Diagnostic Methods for Infectious Diseases

Chapter 1: Introduction

This chapter includes:

- Document scope and applicable exclusions
- Background information pertinent to the document content
- Standard precautions information
- “Note on Terminology” that highlights particular use and/or variation in use of terms and/or definitions
- Terms and definitions used in the document
- Abbreviations and acronyms used in the document

1.1 Scope

This document describes general principles for the development, evaluation, and application of tests designed for direct detection of microorganisms in clinical specimens and for identification of microorganisms grown in culture. The document provides evidence-based recommendations, where appropriate.

The following content areas are addressed:

- Clinical applications
- Amplified and nonamplified nucleic acid methods
- Selection and qualification of nucleic acid sequences
- Establishment and evaluation of test performance characteristics, inhibitors, and interfering substances
- Controlling false-positive reactions
- Reporting and interpretation of results
- QA
- Regulatory issues
- Recommendations for manufacturers and clinical laboratories

This document is intended for use by clinical laboratories, test developers and manufacturers, and regulatory agencies. It is not intended to be a compilation of successful protocols for